BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28662963)

  • 1. Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen.
    Yuki H; Kikuzato K; Koda Y; Mikuni J; Tomabechi Y; Kukimoto-Niino M; Tanaka A; Shirai F; Shirouzu M; Koyama H; Honma T
    Bioorg Med Chem; 2017 Aug; 25(16):4259-4264. PubMed ID: 28662963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
    Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
    Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
    J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pyrrolo-pyrimidine derivative targets human primary AML stem cells in vivo.
    Saito Y; Yuki H; Kuratani M; Hashizume Y; Takagi S; Honma T; Tanaka A; Shirouzu M; Mikuni J; Handa N; Ogahara I; Sone A; Najima Y; Tomabechi Y; Wakiyama M; Uchida N; Tomizawa-Murasawa M; Kaneko A; Tanaka S; Suzuki N; Kajita H; Aoki Y; Ohara O; Shultz LD; Fukami T; Goto T; Taniguchi S; Yokoyama S; Ishikawa F
    Sci Transl Med; 2013 Apr; 5(181):181ra52. PubMed ID: 23596204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo[2,3-d]pyrimidines as potent Hsp90 inhibitors.
    Lee JH; Shin SC; Seo SH; Seo YH; Jeong N; Kim CW; Kim EE; Keum G
    Bioorg Med Chem Lett; 2017 Jan; 27(2):237-241. PubMed ID: 27914802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Hck inhibitors as hits for the development of antileukemia and anti-HIV agents.
    Tintori C; Laurenzana I; La Rocca F; Falchi F; Carraro F; Ruiz A; Esté JA; Kissova M; Crespan E; Maga G; Biava M; Brullo C; Schenone S; Botta M
    ChemMedChem; 2013 Aug; 8(8):1353-60. PubMed ID: 23813855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
    Stauffer F; Cowan-Jacob SW; Scheufler C; Furet P
    Bioorg Med Chem Lett; 2016 Apr; 26(8):2065-7. PubMed ID: 26951750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2.
    Guillon J; Le Borgne M; Rimbault C; Moreau S; Savrimoutou S; Pinaud N; Baratin S; Marchivie M; Roche S; Bollacke A; Pecci A; Alvarez L; Desplat V; Jose J
    Eur J Med Chem; 2013 Jul; 65():205-22. PubMed ID: 23711832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
    Zhang C; Pei H; He J; Zhu J; Li W; Niu T; Xiang M; Chen L
    Eur J Med Chem; 2019 May; 169():121-143. PubMed ID: 30875504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
    Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors.
    Musumeci F; Sanna M; Grossi G; Brullo C; Fallacara AL; Schenone S
    Curr Med Chem; 2017; 24(19):2059-2085. PubMed ID: 28266267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-(Piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine Derivatives as Akt Inhibitors.
    Liu Y; Yin Y; Zhang J; Nomie K; Zhang L; Yang D; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2016 May; 349(5):356-62. PubMed ID: 26991997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
    Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
    Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
    Norman P
    Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.